ADC Therapeutics SA ADCT
1.30 USD -0.07 (-5.11%)
Regular-session close
1.29 -0.01 -0.77%
After hours · Nov 19, 5:59 PM ET
1.29 Day range 1.41
0.78 52-week range 4.98
- YTD
- -63.17%
- 1 year
- -67.66%
Benzinga news
benzinga.com ADC Therapeutics Q3 Adj. EPS $(0.06) Beats $(0.21) Estimate, Sales $21.716M Beat $18.692M Estimate ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.21) by 71.43 percent. This is a 68.42 percent increase over losses of…
benzinga.com ADC Therapeutics' Licensing Partner Tanabe Pharma Files Japanese Marketing Authorization Application For ZYLONTA For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma In addition, Tanabe Pharma has entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd., for the commercialization of ZYNLONTA in Japan.Recently, encouraging results from the…
